Akero Therapeutics Croissance future

Future contrôle des critères 0/6

Akero Therapeutics devrait augmenter ses bénéfices et son chiffre d'affaires de 6.4% et de 72.4% par an respectivement. Le BPA devrait croître de de 11.6% par an. Le rendement des capitaux propres devrait être -186.1% dans 3 ans.

Informations clés

6.4%

Taux de croissance des bénéfices

11.6%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.3%
Taux de croissance des recettes	72.4%
Rendement futur des capitaux propres	-186.1%
Couverture par les analystes	Good
Dernière mise à jour	12 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Prévisions de croissance des bénéfices et des revenus

NasdaqGS:AKRO - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	36	-338	-309	-303	4
12/31/2025	N/A	-320	-291	-257	5
12/31/2024	N/A	-265	-189	-161	5
9/30/2024	N/A	-237	-213	-212	N/A
6/30/2024	N/A	-204	-192	-191	N/A
3/31/2024	N/A	-179	-156	-156	N/A
12/31/2023	N/A	-152	-145	-145	N/A
9/30/2023	N/A	-120	-122	-122	N/A
6/30/2023	N/A	-116	-97	-97	N/A
3/31/2023	N/A	-112	-94	-94	N/A
12/31/2022	N/A	-112	-93	-93	N/A
9/30/2022	N/A	-121	-94	-94	N/A
6/30/2022	N/A	-110	-84	-84	N/A
3/31/2022	N/A	-112	-84	-84	N/A
12/31/2021	N/A	-101	-80	-80	N/A
9/30/2021	N/A	-98	-76	-76	N/A
6/30/2021	N/A	-95	-75	-75	N/A
3/31/2021	N/A	-82	-78	-78	N/A
12/31/2020	N/A	-79	-71	-71	N/A
9/30/2020	N/A	-65	-59	-59	N/A
6/30/2020	N/A	-59	-59	-59	N/A
3/31/2020	N/A	-50	-41	-41	N/A
12/31/2019	N/A	-44	-36	-36	N/A
9/30/2019	N/A	-90	-26	-26	N/A
6/30/2019	N/A	-86	-15	-15	N/A
3/31/2019	N/A	-87	-15	-10	N/A
12/31/2018	N/A	-82	-10	-5	N/A
9/30/2018	N/A	-22	-9	-4	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: AKRO devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: AKRO devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: AKRO devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: AKRO ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: AKRO ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: AKRO devrait être non rentable dans 3 ans.

Akero Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 13% to US$48.38

Price target decreased by 29% to US$48.44

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Price target increased to US$52.00

Price target increased to US$48.33

Recent updates

Akero Therapeutics, Inc. to Showcase New Analyses of Phase 2b Harmony Study in Presentations at 75th Annual AASLD The Liver Meeting®? 2024

Akero Therapeutics, Inc. Provides Business Update

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Akero Therapeutics: Good Candidate For The MASH Basket

Insider notifies of intention to sell stock

Insider notifies of intention to sell stock

New major risk - Revenue and earnings growth

Executive VP notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

New major risk - Revenue and earnings growth

Insufficient new directors

Akero Therapeutics Appoints Scott Gangloff as Chief Technology Officer

Robbins Geller Rudman & Dowd LLP Files Class Action Lawsuit Against Akero Therapeutics, Inc

Co-Founder notifies of intention to sell stock

Akero Therapeutics' EFX Data Warrants Caution

Akero Therapeutics, Inc. Announces Publication of Phase 2b SYMMETRY Cohort D Study in Clinical Gastroenterology and Hepatology

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $319 million.

Akero Therapeutics Reports Statistically Significant Histological Improvements at Week 96 in Phase 2b HARMONY Study

Price target increased by 13% to US$48.38

Akero: Phase 2b NASH Data Bodes Well For Phase 3 SYNCHRONY Program

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Akero Therapeutics, Inc. Announces First Patients Dosed in Efruxifermin Phase 3 Synchrony Program

President exercised options and sold US$368k worth of stock

Co-Founder recently sold US$440k worth of stock

Price target decreased by 29% to US$48.44

Akero Therapeutics, Inc. Reports Encouraging 36-Week Analysis of 96-Week Phase 2b SYMMETRY Study, with a Trend on Fibrosis Improvement and Statistically Significant Results for NASH Resolution, Markers of Liver Injury and Fibrosis, Insulin Sensitization and Lipoproteins

New major risk - Share price stability

Akero Therapeutics, Inc. to Present Results from Phase 2B Symmetry Study Investigating Efruxifermin in Patients with Compensated Cirrhosis Due to NASH

Akero Therapeutics, Inc. Announces Publication of the Harmony Phase 2B Trial Results in the Lancet Gastroenterology & Hepatology

President notifies of intention to sell stock

Price target increased by 7.3% to US$67.75

Price target increased by 7.7% to US$64.75

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. to Report Results of Phase 2b SYMMETRY Study in October 2023

President exercised options and sold US$920k worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

Akero Therapeutics, Inc.(NasdaqGS:AKRO) dropped from Russell Small Cap Comp Value Index

Co-Founder & Chief Scientific Officer recently sold US$2.1m worth of stock

Co-Founder & Chief Scientific Officer notifies of intention to sell stock

President exercised options and sold US$1.1m worth of stock

Akero Therapeutics, Inc. Releases Topline Data from an Expansion Cohort of the Phase 2B SYMMETRY Study

President exercised options and sold US$1.1m worth of stock

President notifies of intention to sell stock

President exercised options and sold US$1.2m worth of stock

President exercised options and sold US$1.2m worth of stock

Insider notifies of intention to sell stock

Akero Therapeutics, Inc. Announces the Appointment of Patrick Lamy as Senior Vice President, Commercial Strategy

Co-Founder exercised options and sold US$544k worth of stock

Price target increased to US$52.00

Akero Therapeutics, Inc. Completes Enrollment of Phase 2B SYMMETRY Study

President exercised options and sold US$455k worth of stock

Independent Director recently sold US$1.1m worth of stock

President exercised options and sold US$428k worth of stock

Independent Director recently sold US$12m worth of stock

Price target increased to US$48.33

Co-Founder & Chief Scientific Officer exercised options and sold US$299k worth of stock

Akero Therapeutics announces closing of upsized public offering

President notifies of intention to sell stock

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $200.000008 million.

Akero Therapeutics, Inc. Releases Topline Data from HARMONY

Akero adds over 100% rallying peers after NASH success

Akero Therapeutics, Inc. Announces Results from Cohort C of its Phase 2a BALANCED trial in non-alcoholic steatohepatitis

Price target decreased to US$41.67